Skip to main content

Table 4 Association of Lp(a) levels with recurrent CVEs in T2DM patients according to HBA1c status

From: Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study

Lp(a) (mg/dL) Recurrent CVEs/Total Crude model Adjusted model
(153/2284) HR (95% CI) p value HR (95% CI) p value
Total patients 153/2284     
 Lp(a) per-SD increase   1.007 (1.002–1.013) 0.007 1.008 (1.002–1.014) 0.006
 Lp(a) < 10 37/846 Reference   Reference  
 10 ≤ Lp(a) < 30 59/769 1.736 (1.151–2.619) 0.009 1.720 (1.099–2.692) 0.018
 Lp(a) ≥ 30 57/669 1.960 (1.296–2.965) 0.001 2.049 (1.308–3.212) 0.002
HBA1c < 7.0% 74/1146     
 Lp(a) per-SD increase   1.008 (1.001–1.016) 0.024 1.009 (1.001–1.018) 0.023
 Lp(a) < 10 17/427 Reference   Reference  
 10 ≤ Lp(a) < 30 28/373 1.968 (1.077–3.595) 0.028 1.815 (0.949–3.473) 0.072
 Lp(a) ≥ 30 29/346 2.156 (1.185–3.924) 0.012 2.009 (1.051–3.840) 0.035
HBA1c ≥ 7.0% 79/1138     
 Lp(a) per-SD increase   1.006 (0.998–1.014) 0.122 1.009 (1.000–1.018) 0.050
 Lp(a) < 10 20/418 Reference   Reference  
 10 ≤ Lp(a) < 30 31/402 1.520 (0.866–2.667) 0.144 1.571 (0.842–2.932) 0.155
 Lp(a) ≥ 30 28/318 1.816 (1.023–3.223) 0.042 2.162 (1.148–4.073) 0.017
  1. The adjusted model including age, sex, body mass index, currentis smoking, hypertension, dyslipidemia, family history of coronary artery disease, diseased vessels, low-density lipoprotein cholesterol, fasting blood glucose, statin and anti-diabetes drugs use
  2. CVEs cardiovascular events, MI myocardial infarction, CVD cardiovascular disease